⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AgeneBio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AgeneBio
↗Baltimore, MD, USA
AgeneBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for neurological and psychiatric conditions. The company's research is rooted in decades of cognitive neuroscience, specifically targeting hippocampal overactivity to preserve and restore brain function in patients with amnestic mild cognitive impairment (aMCI) and other neurodegenerative diseases.
The company's lead program, AGB101, is a proprietary, once-daily, extended-release formulation of low-dose levetiracetam designed to treat aMCI due to Alzheimer's disease. AgeneBio leverages academic collaborations, particularly with Johns Hopkins University, and has received significant support from the National Institute on Aging (NIA) and the Alzheimer's Drug Discovery Foundation (ADDF).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2008
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Alzheimer's Drug Discovery Foundation (ADDF), National Institute on Aging (NIA)
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2B
Modalities:Small molecule
Active Trials:0
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Johns Hopkins University (Research collaboration), Hager Biosciences (Medicinal chemistry), University of Southern California (Research collaboration)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Michela Gallagher - Founder and CEO
Scientific Founders:Michela Gallagher
LINKS
Website:agenebio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AgeneBio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.